stock surged Tuesday on a broad third-quarter beat that "should allay fears of a market slowdown," an analyst said. The company is well known for Cologuard, a stool-based test that detects colon cancer. Screening revenue, which includes Cologuard tests, grew 22% to $666 million, easily topping…
Continue reading...